Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Acetazolamide

Acetazolamide

Acetazolamide is a carbonic anhydrase inhibitor used to treat a variety of conditions, including glaucoma, altitude sickness, and certain types of edema.
It works by reducing the production of bicarbonate ions, which can help lower intraocular pressure and alleviate other symptoms.
Acetazolamide is also sometimes used off-label for the treatment of seizuires and migraines.
Reserchers can optimize their Acetazolamde studies using PubCompare.ai's AI-driven platform, which helps locate the best research protocols from literature, preprints, and patents while leverageing AI-comparisons to enhance reproducibilty and acuracy.
This powerfull tool can streamline Acetazolamde research and discovery.

Most cited protocols related to «Acetazolamide»

1
Measuring Larval Midgut pH Dynamics
pH was measured in the larval midgut using Thymol blue, m-Cresol purple, Cresol red, Bromocreosol purple, BromoThymol blue, Phenol Red and Congo red indicator dyes (all purchased from Sigma- Aldrich). Indicators were added to melted Drosophila diet (0.1% w/v), immediately mixed, and allowed to cool to room temperature. Larvae of the appropriate genotype were added, and after 2 hours the midgut excised in Schneider’s insect medium (Invitrogen). Micrographs were taken immediately using a Sony CyberShot NEX-C3 mounted on a Leica stereo microscope, as pH remains stable for only a few minutes after dissection. Images were processed using Adobe Photoshop CS5.1. Where noted, the diet was also supplemented with 1 mM Omeprazole (Sigma-Alrdich) or 100 μM acetazolamide (Sigma-Aldrich).
Overend G., Luo Y., Henderson L., Douglas A.E., Davies S.A, & Dow J.A. (2016). Molecular mechanism and functional significance of acid generation in the Drosophila midgut. Scientific Reports, 6, 27242.
Full text: Click here
Publication 2016
3-cresol purple Acetazolamide Bromthymol Blue Diet Dissection Drosophila Dyes Genotype Insecta Larva Microscopy Omeprazole thymol blue
2
Acetazolamide for Intracranial Hypertension
A specific dietary plan and lifestyle modification program was offered to all study participants through the New York Obesity Nutrition Research Center; this is described in the eMethods in the Supplement.
The study drug was acetazolamide (250 mg) or matching placebo tablets. The initial dosage of study drug was 4 tablets daily in 2 divided doses, followed by dosage increases of 1 tablet every week up to a maximum dosage of 4 g/d for participants receiving acetazolamide. We chose this maximum dosage because increasing dosages of acetazolamide with concomitant intracranial pressure monitoring showed gradual CSF pressure reduction once participants reached a dosage of 4 g/d.12 (link) The dosage escalation was stopped if the participant’s papilledema grade (Frisén scale)15 (link),16 (link) became less than 1 in both eyes and the PMD improved to equal to or better than −1 dB in each eye, unless the presence of other symptoms such as headache or pulse synchronous tinnitus suggested that the dosage escalation continue. Participants who were unable to tolerate the study drug could gradually decrease the dosage to a minimum of one-half tablet daily. Participants who discontinued study drug continued to be followed up, if willing, for the planned 6-month duration.
Treatment failure was defined when a participant with baseline PMD up to −3.5 dB had visual function worsen by more than 2 dB PMD from baseline in either eye, or when a participant with baseline PMD between −3.5 dB and −7 dB had visual function worsen by more than 3 dB PMD from baseline in either eye, confirmed by a second perimetric examination. An adjudication committee, using all available clinical information, needed to confirm that the worsening was most likely due to uncontrolled intracranial pressure and progression of IIH. Participants who experienced treatment failure were withdrawn from further participation in the trial and referred to their physicians for further treatment.
Effect of Acetazolamide on Visual Function in Patients With Idiopathic Intracranial Hypertension and Mild Visual Loss: The Idiopathic Intracranial Hypertension Treatment Trial. (2014). JAMA, 311(16), 1641-1651.
Publication 2014
Acetazolamide Cerebrospinal Fluid Pressure Diet Dietary Supplements Disease Progression Headache Intracranial Pressure Obesity Papilledema Perimetry Physicians Placebos Pulse Rate Tablet Tinnitus Vision
3
Measuring L-Lactate Transport in Rat Erythrocytes
L-Lactate transport into rat erythrocytes was measured by monitoring the change in extracellular pH with a pH-sensitive electrode as described previously [37 (link),38 (link)]. The cells were used at 3.5% or 7% haematocrit in lightly buffered saline medium supplemented with 5 μM DIDS and 100 μM acetazolamide to prevent bicarbonate/CO2-mediated proton movements [37 (link),38 (link)]. The erythrocytes were pre-incubated for 1 h at room temperature (22–25 °C) with or without AR-C155858 at the required concentration prior to assaying lactate transport. This was performed at 6 °C with substrate uptake initiated by addition of 10 mM L-lactate. Initial rates of transport were calculated by first-order regression analysis of the time course of pH change and converted into nmol of H+ per min by determining the pH change induced by small additions of standardized NaOH.
Ovens M.J., Davies A.J., Wilson M.C., Murray C.M, & Halestrap A.P. (2010). AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10. Biochemical Journal, 425(Pt 3), 523-530.
Publication 2009
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid Acetazolamide AR C155858 Bicarbonates Cells Erythrocytes Lactates Movement Protons Saline Solution Volumes, Packed Erythrocyte
4
Intracranial Hypertension Treatment Trial
The study was approved by each site’s institutional review board and written informed consent was obtained from patients. The tenets of the Declaration of Helsinki were followed. One hundred sixty-five patients with IIH with mild visual loss were enrolled at 38 NORDIC sites in the United States and Canada over a 3-year period. Patients were included if they met the modified Dandy criteria for IIH (eBox 1 in the Supplement) and had perimetric mean deviation (PMD) between −2 and −7 dB on 24-2 SITA (Swedish interactive thresholding algorithm) Standard testing that was reproducible; −2 dB was chosen so that patients would have room to improve and −7 dB was chosen because some investigators believed surgical treatments were necessary for those with more severe visual loss. eBox 2 in the Supplement outlines the major eligibility criteria for the IIHTT.
Patients were randomly assigned to receive a supervised low-sodium diet either with acetazolamide or with matching placebo. A specific dietary plan and lifestyle modification intervention was offered to all study participants with a study weight loss counselor provided by the New York Obesity and Nutrition Research Center. The target weight-loss goal at 6 months was 6% loss of total body weight.
The study drug was acetazolamide, 250 mg, or matching placebo tablets. The initial dosage of study drug was 4 tablets daily in 2 divided doses followed by dosage increases of 1 tablet every week up to a maximum dosage of 4 g daily. We chose this maximum dosage because increasing dosages of acetazolamide with concomitant intracranial pressure monitoring showed gradual CSF pressure reduction once patients reached a dosage of 4 g per day.7 (link) The dosage titration was stopped if the participant’s papilledema grade (Frisén scale)8 (link),9 (link) became less than 1 in both eyes and the PMD improved to equal to or better than −1 dB in each eye, unless the presence of other symptoms, such as headache or pulse synchronous tinnitus, suggested that the dosage titration continue. Patients who were unable to tolerate the study drug could gradually decrease the dosage to a minimum of one-half tablet daily. Patients who discontinued the study drug continued to be followed up, if willing, for the planned 6-month duration.
Treatment failure was defined when a patient with baseline PMD up to −3.5 dB had visual function worsen by more than 2 dB PMD from baseline in either eye or when a patient with baseline PMD between −3.5 dB and −7 dB had visual function worsen by more than 3 dB PMD from baseline in either eye, confirmed by a second perimetric examination. Using all available clinical information, an adjudication committee needed to decide whether the worsening was most likely due to uncontrolled intracranial pressure and progression of IIH. Patients who experienced treatment failure were withdrawn from further participation in the trial.
Outcome variables were assessed at baseline and at follow-up visits, with end-of-study assessments (6 months) being of primary interest. The primary outcome variable was the change from baseline to 6 months in the PMD of the eye with the worst PMD at baseline.
Wall M., Kupersmith M.J., Kieburtz K.D., Corbett J.J., Feldon S.E., Friedman D.I., Katz D.M., Keltner J.L., Schron E.B, & McDermott M.P. (2014). The Idiopathic Intracranial Hypertension Treatment Trial: Clinical Profile at Baseline. JAMA neurology, 71(6), 693-701.
Publication 2014
Acetazolamide Cerebrospinal Fluid Pressure Counselors Diet Dietary Supplements Disease Progression Eligibility Determination Ethics Committees, Research Headache Human Body Intracranial Pressure Low-Sodium Diet Obesity Operative Surgical Procedures Papilledema Patients Perimetry Placebos Pulse Rate Strabismus Tablet Tinnitus Titrimetry Vision
5
Vasodilator Effects on Cerebrovascular Hemodynamics
Studies were categorized by treatment allocation, population characteristics (healthy vs. disease), treatment within 7 days (for populations with an acute stroke), single dose vs. ongoing treatment and crossover vs. parallel group design. Outcome measures included peak systolic (PSV), MFV, end diastolic velocity (EDV) and Gosling's pulsatility index [(PSV – EDV)/MFV] on transcranial ultrasound. For studies reporting mean CBF on MRI, computed tomography (CT) or other perfusion-based imaging methods, mean CBF and the SD of CBF at follow-up were converted into the standardized mean difference (SMD) between treatment groups (difference in means/pooled SD), and transformed to normalize effect size distribution (Hedge's g). Responses to CVR tests (breath-holding, inhaled CO2 5–8%, acetazolamide challenge or the response to hyperventilation) were expressed as SMD for percentage change in CBF or MFV after a vasodilating stimulus compared with the prestimulus measurement (Hedge's g).
Comparisons were combined in meta-analyses by the difference of absolute mean values at follow-up for TCD studies and by the SMD of effects at follow-up for CBF and CVR, weighted by the inverse variance [15 (link)]. For meta-analyses combining absolute measures, the inverse variance of comparisons that did not report the SD at follow-up were imputed from the ratio of the study size to the size of all studies reporting the SD at follow-up. Sensitivity analyses were performed including only studies reporting the SD at follow-up. Studies reporting comparisons of more than one vasodilator vs. a single control group were included as separate comparisons, but only including the number of individuals from one arm for estimation of the inverse variance in imputed values or in calculation of the inverse variance of the SMD. Sensitivity analyses were performed with the inverse variance of the studies divided by the number of comparisons with the same control group. Crossover studies were included as individual comparisons without adjustment for intra-group correlation because of the lack of available data, but sensitivity analyses were performed stratifying effects by crossover design.
The principal outcomes were the effect of treatment with a vasodilating medication compared to a non-vasodilating medication, placebo or no change in treatment, on ΔMFV, Δ pulsatility index, ΔCBF, or reactivity to CO2, with secondary outcomes on PSV or EDV, SBP, DBP and pulse pressure. As few studies reported effects on pulse pressure, study-specific estimates were generated from the difference in group mean SBP and DBP. Analyses were stratified by study design, comparisons with antihypertensives or no active treatment as the control group, by the active drug class, by method of measurement of CBF or reactivity to CO2, by population demographics, disease duration and acuity of treatment.
To assess the presence of treatment interactions with study design, treatment acuity or population characteristics, determinants of effect size (SMD or absolute differences) and their interactions with treatment were identified from general linear models, weighted by the inverse variance.
, & Webb A.J. (2018). Effects of vasodilating medications on cerebral haemodynamics in health and disease: systematic review and meta-analysis. Journal of Hypertension, 37(6), 1119-1125.
Full text: Click here
Publication 2018
Acetazolamide Acute Cerebrovascular Accidents Antihypertensive Agents Diastole Hypersensitivity Pharmaceutical Preparations Placebos Pulse Pressure Systole Ultrasonography Vasodilator Agents X-Ray Computed Tomography

Most recents protocols related to «Acetazolamide»

1
Cerebrovascular Reactivity Calculation
Using the estimated Ca10 as an input function, rCBFs at rest and after the acetazolamide challenge were calculated. CVR was calculated using the following equation:
CVR = (rCBF after acetazolamide challenge–rCBF at rest) × 100 / rCBF at rest
Kaga T., Kato H., Imai T., Ando T., Noda Y., Miura T., Enomoto Y., Hyodo F., Iwama T, & Matsuo M. (2023). Non-invasive regional cerebral blood flow quantification in the 123I-IMP autoradiography using artificial neural network. PLOS ONE, 18(3), e0281958.
Full text: Click here
Publication 2023
Acetazolamide
2
SPECT Imaging Protocol for Cerebral Hemodynamics
SPECT was performed using a dual-head gamma camera (InfiniaTM; GE Healthcare, Buckinghamshire, UK) and an ELEGP collimator (GE Healthcare, Buckinghamshire, UK). The energy range was centered at 159 keV with a width of 10%, and a 2-min rotation was performed 14 times in a continuous mode. The matrix size was 64 × 64 pixels.
The procedures of DTARG are presented in Fig 2 [11 (link)]. A two-time intravenous injection of 123I-IMP (111 MBq product, respectively) was administered by a radiologist at a 30-min interval. The injected dose volume was calculated by the following equation:
Injected dose volume (MBq) = 111 × exp (−0.0525 × t)
where t represents the elapsed time from the Japan standard time (UTC +9) of 12:00. SPECT data collection commenced simultaneously with the intravenous injection of 123I-IMP. Dynamic SPECT scanning was performed for 28 min (0–28 and 30–58 min after the start of the first injection of 123I-IMP). Approximately 10 min after the first 123I-IMP intravenous injection, 2 mL of arterial blood was obtained from the radial or femoral artery, and the standard input function was calibrated. The sample arterial blood radioactivity concentration was measured using a well counter (DCM-200TM; ALOKA, Tokyo, Japan). Approximately 20 min after the first 123I-IMP intravenous injection, 1,000 mg of acetazolamide was intravenously administered. The cross-calibration factor (CCF) between the SPECT images and the well counter system was determined in advance by comparing the average pixel counts derived from the regions of interest (ROIs) on the reconstructed emission images and the well counter radioactivity-counting rate.
The uniformity correction and center-of-rotation calibration were performed using the clinical routine software on the SPECT system. Stereotactic anatomic standardization was also performed on the scan data using three-dimensional stereotactic surface projections (3D-SSP, Nihon Medi-Physics, Tokyo, Japan) [12 (link)]. The ROIs were placed on the standardized images both at rest and following the acetazolamide challenge, using an automatic ROI definition software (NEURO FLEXER, Nihon Medi-Physics, Tokyo, Japan) [13 (link)]. This software automatically placed three-dimensional ROIs on 10 arterial territories, including the bilateral anterior cerebral artery, bilateral middle cerebral artery (MCA), bilateral anterior part of MCA, bilateral posterior part of MCA, and bilateral posterior cerebral artery. The ROIs were also placed on 10 segments, including the bilateral hemisphere, bilateral basal ganglia, bilateral thalamus, bilateral cerebellar hemisphere, pons, and vermis of the cerebellum (Fig 3).
Kaga T., Kato H., Imai T., Ando T., Noda Y., Miura T., Enomoto Y., Hyodo F., Iwama T, & Matsuo M. (2023). Non-invasive regional cerebral blood flow quantification in the 123I-IMP autoradiography using artificial neural network. PLOS ONE, 18(3), e0281958.
Full text: Click here
Publication 2023
Acetazolamide Arteries Basal Ganglia BLOOD Cerebellum Cerebral Arteries, Anterior Femoral Artery Gamma Cameras Head Iodine-123 Middle Cerebral Artery Pons Posterior Cerebral Artery Radioactivity Radiologist Radionuclide Imaging Thalamus Tomography, Emission-Computed, Single-Photon Vermis, Cerebellar
3
Cerebral Blood Flow Dynamics in MS
Anonymised data from sixteen subjects enrolled in a clinical study were included in the present work. Eight subjects were healthy controls (mean age 38.6), and eight subjects were diagnosed with multiple sclerosis (MS) (mean age 43.1). MS patients' data were included due to their scans being available from a clinical parent study involving the investigation of the effect of acetazolamide on CBF in MS patients. 15O–water PET data with accompanying blood measures are rare and so all data from this other study were included to maximise the amount of data available. All subjects gave their informed consent before inclusion, and the study was approved by the medical ethics review board in Uppsala (2014/453).
Each subject underwent two dynamic PET scans both starting simultaneously with a controlled bolus injection of 5 MBq/kg of 15O–water (10 ml at 1 ml/s followed by a 30-ml saline flush at 2 ml/s) on a GE Discovery MI PET/CT scanner (GE Healthcare, Waukesha) [29 (link)]. Approximately 10 min before the second scan, the subjects were administered acetazolamide (9 mg/kg up to 1 g). The pharmacological manipulation was not of interest to the current study—all scans were included. The time between scan starts was approximately 20 min to allow for radioactive decay.
Young P., Appel L., Tolf A., Kosmidis S., Burman J., Rieckmann A., Schöll M, & Lubberink M. (2023). Image-derived input functions from dynamic 15O–water PET scans using penalised reconstruction. EJNMMI Physics, 10, 15.
Full text: Click here
Publication 2023
Acetazolamide BLOOD Flushing Multiple Sclerosis Parent Patients Positron-Emission Tomography Radioactivity Radionuclide Imaging Saline Solution Scan, CT PET
4
Meldonium Mitigates Hypoxia Effects
To evaluate the effect of pre-administrated with meldonium under acute high-altitude hypoxia, SD rats (6 in each group) were administered by gavage and randomly divided into normoxia group, hypoxia group (model group), hypoxia groups with differential dose meldonium (25, 50, 100, 200, and 400 mg/kg), and hypoxia with acetazolamide group (positive control). In addition, the pharmacokinetics of meldonium (25, 50, 100 mg/kg) was investigated under acute high-altitude hypoxia in SD rats administered by gavage and/or intravenously. Normoxia group rats given saline lived at an average altitude of 43.5 m, and the acute hypoxia groups were placed in a simulated hypobaric hypoxia chamber with an altitude of 7,000 m for 24 h after 3 days of continuous administration with meldonium.
Liu F., Sui X., Wang Q., Li J., Yang W., Yang Y., Xiao Z., Sun Y., Guo X., Yang X., Yang J., Wang Y, & Luo Y. (2023). Insights into the pharmacodynamics and pharmacokinetics of meldonium after exposure to acute high altitude. Frontiers in Pharmacology, 14, 1119046.
Full text: Click here
Publication 2023
3-(2,2,2-trimethylhydrazine)propionate Acetazolamide Altitude Hypoxia Drug Kinetics Hypoxia Rattus norvegicus Saline Solution Tube Feeding
5
Intravitreal Bevacizumab and Dexamethasone for Ocular Treatment
Patients were prepared with the application of topical 10% iodine-povidone to the eyelids and 5% iodine-povidone eye drops to the conjunctival site of injection. Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL; Hoffmann-La Roche Ltd., Basel, Switzerland) and intravitreal injection of dexamethasone aqueous-solution (200 μg in 0.05 mL) were each administered with a BD Ultra-FineTM 29G½” disposable syringe needle, via the pars plana (3.5 mm from the limb) under topical anesthesia. One 250 mg acetazolamide tablet (Diamox®) was administered orally one hour before the procedure and the dose was repeated 4 h after both intravitreal injections. After the procedure, perfusion of the optic nerve was evaluated by indirect binocular ophthalmoscopy, with paracentesis of the anterior chamber considered in cases of poor perfusion. The patients were instructed to apply antibiotic eye drops (0.5% moxifloxacin), one drop every 4 h to the injected eye, starting 24 h before the injection for prophylaxis and continuing the application for 5 days after the injection.
Clinical ophthalmological evaluations including the same assessments as performed at baseline were performed at 1, 4, 8, 12, 16, 20, and 24 weeks after injections of bevacizumab and dexamethasone. Additional intravitreal injections of the combined drugs were administered if CSFT > 300 μm.
Veiga Reis F., Dalgalarrondo P., da Silva Tavares Neto J.E., Wendeborn Rodrigues M., Scott I.U, & Jorge R. (2023). Combined intravitreal dexamethasone and bevacizumab injection for the treatment of persistent diabetic macular edema (DexaBe study): a phase I clinical study. International Journal of Retina and Vitreous, 9, 13.
Full text: Click here
Publication 2023
Acetazolamide Antibiotics Bevacizumab Chambers, Anterior Conjunctiva Dexamethasone Diamox Eye Drops Eyelids Moxifloxacin Needles Ophthalmoscopy Optic Nerve Paracentesis Patients Perfusion Pharmaceutical Preparations Planum Poly(ADP-ribose) Polymerases Povidone Iodine Syringes Tablet Topical Anesthetics

Top products related to «Acetazolamide»

1
Acetazolamide by Merck Group
Sourced in United States, Germany, Italy, Macao
Acetazolamide is a chemical compound used as a laboratory reagent. It functions as a carbonic anhydrase inhibitor, which is a class of enzymes involved in various physiological processes. The core function of acetazolamide is to inhibit the activity of carbonic anhydrase enzymes, which can be utilized in various research and analytical applications.
2
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
3
Methanol by Merck Group
Sourced in Germany, United States, Italy, India, United Kingdom, China, France, Poland, Spain, Switzerland, Australia, Canada, Sao Tome and Principe, Brazil, Ireland, Japan, Belgium, Portugal, Singapore, Macao, Malaysia, Czechia, Mexico, Indonesia, Chile, Denmark, Sweden, Bulgaria, Netherlands, Finland, Hungary, Austria, Israel, Norway, Egypt, Argentina, Greece, Kenya, Thailand, Pakistan
Methanol is a clear, colorless, and flammable liquid that is widely used in various industrial and laboratory applications. It serves as a solvent, fuel, and chemical intermediate. Methanol has a simple chemical formula of CH3OH and a boiling point of 64.7°C. It is a versatile compound that is widely used in the production of other chemicals, as well as in the fuel industry.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
Bumetanide by Merck Group
Sourced in United States, United Kingdom, Germany, Denmark
Bumetanide is a pharmaceutical compound used as a loop diuretic. It functions by inhibiting the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water.
6
Amiloride by Merck Group
Sourced in United States, Germany, Italy, Sao Tome and Principe, United Kingdom, Macao, China, Denmark
Amiloride is a laboratory product manufactured by Merck Group. It is a small molecule compound primarily used as a research tool in scientific investigations. Amiloride functions as a potassium-sparing diuretic, inhibiting the sodium-hydrogen exchanger and the epithelial sodium channel.
7
Stopped flow instrument by Applied Photophysics
Sourced in United Kingdom
The Stopped-flow instrument from Applied Photophysics is a laboratory equipment used to rapidly mix and analyze small volumes of sample solutions. It is designed to capture and record the initial, fast-occurring changes in a chemical or biological reaction over time.
8
Goldmann applanation tonometry by Haag-Streit
Sourced in Switzerland, Germany
Goldmann applanation tonometry is a device used to measure intraocular pressure (IOP) within the eye. It works by gently flattening a portion of the cornea and measuring the force required to achieve this flattening. The device provides an objective and quantitative measurement of IOP, which is a crucial parameter in the diagnosis and management of conditions such as glaucoma.
9
Gamma counter by PerkinElmer
Sourced in United States
The Gamma counter is a laboratory instrument used to measure the radioactivity of samples. It detects and quantifies gamma radiation emitted by radioactive isotopes present in the samples.
10
Indomethacin by Merck Group
Sourced in United States, Germany, United Kingdom, Brazil, Italy, Sao Tome and Principe, China, India, Japan, Denmark, Australia, Macao, Spain, France, New Zealand, Poland, Singapore, Switzerland, Belgium, Canada, Argentina, Czechia, Hungary
Indomethacin is a laboratory reagent used in various research applications. It is a non-steroidal anti-inflammatory drug (NSAID) that inhibits the production of prostaglandins, which are involved in inflammation and pain. Indomethacin can be used to study the role of prostaglandins in biological processes.

More about "Acetazolamide"

Acetazolamide is a carbonic anhydrase inhibitor that has a wide range of applications in the medical field.
It is commonly used to treat glaucoma, altitude sickness, and certain types of edema by reducing the production of bicarbonate ions, which can help lower intraocular pressure and alleviate other symptoms.
Additionally, acetazolamide is sometimes used off-label for the treatment of seizures and migraines.
Researchers can optimize their acetazolamide studies using PubCompare.ai's AI-driven platform, which helps locate the best research protocols from literature, preprints, and patents while leveraging AI-comparisons to enhance reproducibility and accuracy.
This powerful tool can streamline acetazolamide research and discovery.
Acetazolamide is often used in conjunction with other compounds, such as DMSO, methanol, and FBS, to enhance its effectiveness or study its pharmacokinetics.
Related medications like bumetanide and amiloride may also be used in similar applications.
Specialized equipment, such as a stopped-flow instrument, Goldmann applanation tonometry, and a gamma counter, may be utilized in acetazolamide research to measure various parameters.
Indomethacin, another medication, is sometimes used in conjunction with acetazolamide to study its effects on the body.
By incorporating these related terms and concepts, researchers can gain a more comprehensive understanding of the various applications and nuances of acetazolamide research and discovery.